RxDoctor Payments Data

Athar Shaikh, MD

Internal Medicine · Nogales, AZNPI 1477531713

Payments from drug & device makers

$937in general payments, 2019–2025

Across 50 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$198
  • Nestle Healthcare Nutrition Inc.$125
  • Novo Nordisk$96
  • Abbott$79
  • Bayer$65
  • Johnson & Johnson$60
  • plus $313 from 8 others

What the payments were for

  • Food & beverage$937100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$937 in reported general payments places this provider in the 75th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$115,406
Medicare patients
190
Services billed
1,546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide170$191,342
MounjaroTirzepatide99$111,395
EliquisApixaban111$100,629
JardianceEmpagliflozin80$95,021
OzempicSemaglutide76$74,368
FarxigaDapagliflozin Propanediol35$48,655
XareltoRivaroxaban26$38,517
EntrestoSacubitril/Valsartan19$19,976
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$18,303
LantusInsulin Glargine,hum.Rec.Anlog95$15,023
Repatha SureclickEvolocumab21$13,644
Atorvastatin Calcium991$13,575
Tresiba Flextouch U-100Insulin Degludec22$12,187
MyrbetriqMirabegron15$11,260
Lantus SolostarInsulin Glargine,hum.Rec.Anlog91$10,487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$53$302,738269 claims
PfizerEliquis$58$100,629111 claims
Novo NordiskOzempic$96$74,36876 claims
AstraZenecaFarxiga$198$48,65535 claims
Johnson & JohnsonXarelto$60$38,51726 claims
NovartisEntresto$29$19,97619 claims
Sanofi-aventis U.S. LLCLantus$50$15,02395 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Nogales

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →